Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N)

Molecular Cancer Therapeutics

Volumn 8, Issue 5, 2009, Pages 1261-1269

  Mehibel, Manal ^a   Singh, Simendra ^a,b   Chinje, Edwin C ^a,c   Cowen, Rachel L ^a   Stratford, Ian J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c NBGW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; ANTINEOPLASTIC AGENT; AQ 4; AQM; BANOXANTRONE; CYTOKINE; DRUG METABOLITE; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BYSTANDER EFFECT; CELL CULTURE; CELL CYCLE; CELL FUNCTION; CELL KILLING; CELL PROLIFERATION; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVATION; DRUG METABOLISM; DRUG RESPONSE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPOXIA; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR CELL LINE;

ANIMALS; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL HYPOXIA; CELL LINE; CELL SURVIVAL; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MACROPHAGES; MICE; NEOPLASMS; NITRIC OXIDE SYNTHASE TYPE II; TRIAZINES;

EID: 66849109065     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0927     Document Type: Article

References (50)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867
2. + macrophages in antitumor cytotoxicity. Lab Invest 1992;67:166-174
3. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002;196:254-265 (Pubitemid 34189413)
4. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-266 (Pubitemid 43121975)
5. Wink DA, Vodovotz Y, Laval J, et al. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998;19:711-721 (Pubitemid 28376759)
6. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997;15:323-350 (Pubitemid 27169284)
7. Thomsen LL, Miles DW, Happerfield L, et al. Nitric oxide synthase activity in human breast cancer. Br J Cancer 1995;72:41-44
8. Tendler DS, Bao C,Wang T, et al. Intersection of interferon and hypoxia signal transduction pathways in nitric oxide-induced tumor apoptosis. Cancer Res 2001;61:3682-3688 (Pubitemid 32694980)
9. Keller R, Geiges M, Keist R. L-arginine-dependent reactive nitrogen intermediates as mediators of tumor cell killing by activated macrophages. Cancer Res 1990;50:1421-1425
10. Andrade SP, Hart IR, Piper PJ. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br J Pharmacol 1992;107:1092-1095
11. Jenkins DC, Charles IG, Thomsen LL, et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A 1995;92:4392-4396
12. Hemmens B, Mayer B. Enzymology of nitric oxide synthases. Methods Mol Biol 1998;100:1-32.
13. Bredt DS, Hwang PM, Glatt CE, et al. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 1991;351:714-718 (Pubitemid 21896670)
14. Garner AP, Paine MJ, Rodriguez-Crespo I, et al. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Res 1999;59:1929-1934 (Pubitemid 29186167)
15. Bachur NR, Gordon SL, Gee MV, Kon H. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci U S A 1979;76:954-957 (Pubitemid 9130981)
16. Saunders MP, Patterson AV, Chinje EC, Harris AL, Stratford IJ. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line. Br J Cancer 2000;82:651-656
17. Chinje EC, Cowen RL, Feng J, et al. Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro. Mol Pharmacol 2003;63:1248-1255 (Pubitemid 36627219)
18. Patterson AV, Saunders MP, Chinje EC, et al. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer 1997;76:1338-1347
19. Newell DR, Searle KM, Westwood NB, Burtles SS. Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK. Br J Cancer 2003;89:437-454 (Pubitemid 37028340)
20. Patterson LH, McKeown SR. AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br J Cancer 2000;83:1589-1593 (Pubitemid 32001698)
21. McKeown SR, Hejmadi MV, McIntyre IA, McAleer JJ, Patterson LH. AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer 1995;72:76-81.
22. Murdoch C, Lewis CE. Macrophage migration and gene expression in response to tumor hypoxia. Int J Cancer 2005;117:701-708 (Pubitemid 41598819)
23. Brown JM. The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1999;59:5863-5870
24. Fuchs T, Chowdhury G, Barnes CL, Gates KS. 3-Amino-1,2,4-benzotriazine 4-oxide: characterization of a new metabolite arising from bioreductive processing of the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine). J Org Chem 2001;66:107-114 (Pubitemid 32057846)
25. Dong Z, Staroselsky AH, Qi X, Xie K, Fidler IJ. Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res 1994;54:789-793 (Pubitemid 24068338)
26. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985;150:76-85. (Pubitemid 16258399)
27. Swaine DJ, Loadman PM, Bibby MC, Graham MA, Patterson LH. High-performance liquid chromatographic analysis of AQ4N, an alkylaminoanthraquinone N-oxide. J Chromatogr B Biomed Sci Appl 2000;742:239-245 (Pubitemid 30331041)
28. Jounaidi Y, Waxman DJ. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res 2000;60:3761-3769 (Pubitemid 32204566)
29. Leek RD, Landers RJ, Harris AL, Lewis CE. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 1999;79:991-995 (Pubitemid 29082138)
30. Bugelski PJ, Kirsh R, Buscarino C, Corwin SP, Poste G. Recruitment of exogenous macrophages into metastases at different stages of tumor growth. Cancer Immunol Immunother 1987;24:93-98 (Pubitemid 17055310)
31. Bugelski PJ, Corwin SP, North SM, et al. Macrophage content of spontaneous metastases at different stages of growth. Cancer Res 1987;47:4141-4145 (Pubitemid 17108484)
32. Saura M, Zaragoza C, Bao C, McMillan A, Lowenstein CJ. Interaction of interferon regulatory factor-1 and nuclear factor κB during activation of inducible nitric oxide synthase transcription. J Mol Biol 1999;289:459-471 (Pubitemid 29295117)
33. Nishida CR, Ortiz de Montellano PR. Reductive heme-dependent activation of the N-oxide prodrug AQ4N by nitric oxide synthase. J Med Chem 2008;51:5118-5120
34. Siegert A, Rosenberg C, Schmitt WD, Denkert C, Hauptmann S. Nitric oxide of human colorectal adenocarcinoma cell lines promotes tumour cell invasion. Br J Cancer 2002;86:1310-1315 (Pubitemid 34888185)
35. Konur A, Krause SW, Rehli M, Kreutz M, Andreesen R. Human monocytes induce a carcinoma cell line to secrete high amounts of nitric oxide. J Immunol 1996;157:2109-2115 (Pubitemid 126449688)
36. Smith PJ, Desnoyers R, Blunt N, et al. Flow cytometric analysis and confocal imaging of anticancer alkylaminoanthraquinones and their N-oxides in intact human cells using 647-nm krypton laser excitation. Cytometry 1997;43-53. (Pubitemid 27059781)
37. Leek RD, Lewis CE, Whitehouse R, et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996;56:4625-4629 (Pubitemid 26338061)
38. Lee AH, Happerfield LC, Bobrow LG, Millis RR. Angiogenesis and inflammation in invasive carcinoma of the breast. J Clin Pathol 1997;50:669-673 (Pubitemid 27396070)
39. Fujimoto J, Sakaguchi H, Aoki I, Tamaya T. Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers. Cancer Res 2000;60:2632-2635 (Pubitemid 30318237)
40. Salvesen HB, Akslen LA. Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int J Cancer 1999;84:538-543
41. Hanada T, Nakagawa M, Emoto A, et al. Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol 2000;7:263-269 (Pubitemid 30440592)
42. Migita T, Sato E, Saito K, et al. Differing expression of MMPs-1 and -9 and urokinase receptor between diffuse- and intestinal-type gastric carcinoma. Int J Cancer 1999;84:74-79 (Pubitemid 29059112)
43. Kerr KM, Johnson SK, King G, et al. Partial regression in primary carcinoma of the lung: does it occur? Histopathology 1998;33:55-63.
44. Koukourakis MI, Giatromanolaki A, Kakolyris S, et al. Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival. Br J Cancer 1998;77:1696-1703 (Pubitemid 28230477)
45. Hakansson L, Adell G, Boeryd B, Sjogren F, Sjodahl R. Infiltration of mononuclear inflammatory cells into primary colorectal carcinomas: an immunohistological analysis. Br J Cancer 1997;75:374-380 (Pubitemid 27051052)
46. Nakayama Y, Nagashima N, Minagawa N, et al. Relationships between tumor-associated macrophages and clinicopathological factors in patients with colorectal cancer. Anticancer Res 2002;22:4291-4296 (Pubitemid 36134475)
47. Forssell J, Oberg A, Henriksson ML, et al. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 2007;13:1472-1479 (Pubitemid 46450437)
48. Fitzpatrick B, Mehibel M, Cowen RL, Stratford IJ. iNOS as a therapeutic target for treatment of human tumors. Nitric Oxide 2008;19:217-224
49. Chinje EC, Williams KJ, Telfer BA, et al. 17β-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response. Br J Cancer 2002;86:136-142 (Pubitemid 34146354)
50. Ridnour LA, Thomas DD, Switzer C, et al. Molecular mechanisms for discrete nitric oxide levels in cancer. Nitric Oxide 2008;19:73-76